Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Donanemab raised the risk of amyloid-related imaging abnormalities (ARIA) in Alzheimer's patients. Many ARIA events ...

New research shows that lecanemab and donanemab can slow cognitive decline ... samples for amyloid beta (Aβ) and tau protein assessment. All participants underwent clinical and cognitive ...

A third agent in the class, donanemab (Kisunla), gained FDA approval ... microglia to ingest and eliminate fibrillar amyloid-beta (Aβ), according to a review in BioDrugs. "Each of the approved ...

But some experts say the side effects of the drug called donanemab may outweigh its benefits. It was given the green light by UK drug regulators, the Medicines and Healthcare Products Regulatory ...

But some experts have long warned that side effects of the drug — called donanemab — massively outweigh its benefits. Now, a new study from the company that produces the medication itself ...

Today we’ve published further draft guidance for public consultation that continues to not recommend Alzheimer’s treatments donanemab and lecanemab. Our independent committee said last year that the ...

Lecanemab and donanemab were hailed as 'the beginning of the end' of dementia last year, after studies showed they slowed the progression of memory-robbing illness in its early stages by up to 35 ...

Your doctor might suggest taking one of the newer medications such as lecanemab or donanemab, which have been shown in clinical trials to clear plaque-causing amyloid proteins from the brain that ...

We respond to the disappointing decision NICE has made to not recommend donanemab and lecanemab on the NHS. On Thursday, 6 March, NICE published further draft guidance for public consultation that ...

We respond to the disappointing decision NICE has made to not recommend donanemab and lecanemab on the NHS. We've funded research 30 years ago responsible for identifying the role of the amyloid ...